Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) - The Lancet Oncology

Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Castration-resistant prostate cancer: latest evidence and therapeutic implications - Daniel L. Suzman, Emmanuel S. Antonarakis, 2014

PDF) Long-term complete remission with Ipilimumab in metastatic castrate- resistant prostate cancer: Case report of two patients

Cancers, Free Full-Text

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer - ecancer

Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer

Cancers, Free Full-Text

Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets - The ASCO Post

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650